Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society ...
Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...
Pfizer's Bladder Cancer Therapy Meets Main Goal in Late-Stage Study (Reuters) -Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained ...
Pfizer's Phase III CREST trial evaluating sasanlimab with Bacillus Calmette-Guérin (BCG), as induction treatment with or ...
GlobalData on MSN1d
Pfizer reports positive outcomes from trial of mCRC combination therapyPfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...
“These results reinforce Pfizer’s leadership in genitourinary cancer research and development, demonstrating our ongoing commitment to deliver new treatment options for patients with bladder ...
Zacks.com on MSN15d
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer StudyData from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain bladder cancer patients.
Pfizer's Phase 3 trial showed sasanlimab with BCG improved event-free survival in high-risk NMIBC patients. Sasanlimab's safety profile aligns with known PD-1 inhibitors and BCG data from previous ...
Jan 10 (Reuters) - Pfizer's (PFE.N), opens new tab experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback